FORT LAUDERDALE, Fla.–(Business Wire)–
Nipro Diagnostics, Inc., a leader in diabetes products and a wholly-owned
subsidiary of Nipro Corporation, announced today the appointment of Scott Verner
as President, with responsibility for the Company`s blood glucose monitoring and
insulin pump business in the U.S., effective immediately. Mr. Verner`s
appointment follows on the recent merger announcement between Home Diagnostics,
Inc. and Nipro Diabetes Systems, Inc., which created Nipro Diagnostics, Inc. Mr.
Verner was previously Senior Vice President of Sales & Marketing at Home
Diagnostics and the newly created Nipro Diagnostics.
Luis Candelario, President of Nipro Medical Corporation, commented, “We are
pleased to appoint Scott Verner as President of Nipro Diagnostics. He is a
seasoned healthcare executive with extensive relationships and deep diabetes
industry knowledge. He has already made significant contributions in rebranding
and repositioning Nipro Diagnostics` BGM products, driving adoption of that
product line and improving our sales infrastructure.”
Mr. Candelario added, “The combination of Nipro Diagnostics` blood glucose
monitoring products with the Amigo Insulin Pump provides a substantial platform
to continue building a leading diabetes product company. Scott is a proven
leader and the ideal candidate to leverage this platform and further strengthen
our leadership in the diabetes product market.”
Scott Verner, President of Nipro Diagnostics, Inc., said, “I am excited to
continue making contributions to building Nipro Diagnostics in my new role. Our
product portfolio has further evolved into a comprehensive and competitive
offering, meeting a wide range of unique consumer needs and exceptionally high
standards for both quality and value. We believe those standards will continue
to be the basis of our growth and success over the next several years.”
Mr. Verner joined Home Diagnostics in 2007 as Senior Vice President of Sales &
Marketing, where he was responsible for developing and executing the Company`s
sales and marketing strategy. During his three year tenure, he strengthened the
Company`s sales infrastructure and successfully rebranded and repositioned the
Company`s blood glucose monitoring product line. This included leveraging new
tools to expand the Company`s market reach, broadening the Company`s managed
care relationships, and obtaining Tier 1 or preferred status for the Company`s
products on key managed care formularies.”
Prior to joining Nipro Diagnostics, Mr. Verner was Vice President of Sales at
EyeTel Imaging, a company focused on developing technologies to treat diabetes
and micro-vascular disease. During his tenure at EyeTel Imaging, he was
responsible for the company`s sales, telesales, marketing and national account
and disease management teams. Prior to EyeTel Imaging, Mr. Verner worked for
Allergan, Inc. where he was instrumental in leading the spin-off of Advanced
Medical Optics (AMO). Before Allergan, Mr. Verner spent 12 years at Novartis,
where he held several sales and marketing positions within the company`s medical
device, OTC and pharmaceutical business units.
About Nipro Diagnostics, Inc.
Based in Fort Lauderdale, Florida, Nipro Diagnostics, Inc. is a leading
developer, manufacturer and marketer of diabetes management products. Nipro
Diagnostics offers a portfolio of high-quality blood glucose monitoring products
and systems available throughout the world. Nipro Diagnostics is the exclusive
co-brand supplier of blood glucose monitoring systems for leading pharmacies
including CVS, Rite Aid and Walgreens, as well as distributors such as
AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical.
Nipro Diagnostics, Inc. has previously announced plans to merge with Nipro
Diabetes Systems, Inc. Both companies are wholly-owned by Nipro Corporation, a
multi-billion dollar company headquartered in Osaka, Japan and a world leader in
providing medical products to the healthcare community. Nipro Diabetes Systems,
located in Miramar, Florida, is the manufacturer and marketer of the Amigo
Insulin Pump. The merger of the two companies results in a comprehensive
diabetes monitoring and insulin management product portfolio, which few
companies offer. This portfolio will help to ensure that patients and their
healthcare professionals have easy access to the high-quality diabetes
monitoring and management tools they need to improve quality of life. Both
companies share a vision of making diabetes monitoring and management more
affordable and are already well-positioned in the quality-value segment of their
respective categories.
For more information, please visit www.niprodiagnostics.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6346892〈=en
For Nipro Diagnostics, Inc.
The Ruth Group
Eric Reiss, 646-536-7032
ereiss@theruthgroup.com
Copyright Business Wire 2010